0001127602-17-003935.txt : 20170203 0001127602-17-003935.hdr.sgml : 20170203 20170203172503 ACCESSION NUMBER: 0001127602-17-003935 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170201 FILED AS OF DATE: 20170203 DATE AS OF CHANGE: 20170203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES INC CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MARTIN JOHN C CENTRAL INDEX KEY: 0001190578 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 17573204 MAIL ADDRESS: STREET 1: 333 LAKESIDE DRIVE CITY: FOSTER CITY STATE: X1 ZIP: 94404 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2017-02-01 0000882095 GILEAD SCIENCES INC GILD 0001190578 MARTIN JOHN C GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY CA 94404 1 1 Executive Chairman Common Stock 2017-02-01 4 M 0 73333 21.575 A 3204429 D Common Stock 2017-02-01 4 S 0 73333 72.574 D 3131096 D Non-qualified Stock Option (Right to Buy) 21.575 2017-02-01 4 M 0 73333 0 D 2018-01-30 Common Stock 73333 733330 D The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. The options have a five year vesting schedule. 20% of the options will vest on January 30, 2009, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 30, 2013. Sale prices reported for the transactions reported here range from $72.09 to $72.87. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. /s/ Marissa Song by Power of Attorney for John C. Martin 2017-02-03